Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

NCT03172455 is registered in ClinicalTrials.gov with Impatients N.V. trading as myTomorrows as lead sponsor.

NCT NCT03172455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03172455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
Lead sponsor
Impatients N.V. trading as myTomorrows
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft-versus-host reaction following bone marrow transplant, acute-graft-versus-host disease, alpha 1-antitrypsin deficiency, alpha-1 protease inhibitor deficiency, alpha-1 proteinase inhibitor, graft vs host disease, graft-versus-host-disease, steroid refractory acute graft versus host disease